This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Glaxo gains EU conditional clearance for Novartis vaccines deal

( January 28, 2015, 16:30 GMT | Official Statement) -- MLex Summary: The European Commission has approved GlaxoSmithKline’s plan to buy Novartis’s vaccine business and to take sole control of a new consumer-healthcare joint venture with the Swiss company, subject to conditions. The UK drug giant has agreed to license and divest certain vaccines and to sell several antismoking and cold-sore management products, to alleviate the regulator’s concerns.The full press release follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login